Vertex Pharmaceuticals Incorporated (VRTX) reported second-quarter 2024 adjusted loss per share of $12.83, which was wider than the Zacks Consensus Estimate of a loss of $11.50. In the year-ago quarter, Vertex recorded adjusted earnings of $3.89 per share. The significant loss in the quarter was due to costs related to the $4.9 billion acquisition of Alpine Immune Sciences, which was closed in May. The company reported total revenues of $2.65 billion, comprising cystic fibrosis (CF) product revenues. The fi ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though? Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Vertex Pharmaceuticals (VRTX) . Vertex currently has an average ...

Vertex Pharmaceuticals (VRTX) came out with a quarterly loss of $12.83 per share versus the Zacks Consensus Estimate of a loss of $11.50. This compares to earnings of $3.89 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -11.57%. A quarter ago, it was expected that this drugmaker would post earnings of $4.10 per share when it actually produced earnings of $4.76, delivering a surprise of 16.10%. Over the last four quarters, th ...

Core Viewpoint - Vertex Pharmaceuticals is set to report its second-quarter 2024 results, with revenue expectations at $2.65 billion and earnings at $4.04 per share [1] Group 1: Upcoming Results and Estimates - The consensus estimate for Vertex's 2024 earnings per share (EPS) remains constant at $16.78, while the 2025 EPS forecast has slightly decreased from $17.71 to $17.69 [3] - Vertex has an Earnings ESP of 0.00% and currently holds a Zacks Rank 3 [5] Group 2: Product Portfolio and Market Dynamics - Vertex markets four cystic fibrosis (CF) products: Trikafta/Kaftrio, Symdeko, Orkambi, and Kalydeco [6] - Increased sales of Trikafta/Kaftrio are likely causing a decline in sales of Vertex's other CF drugs [7] - The approval of Casgevy for sickle cell disease and transfusion-dependent beta thalassemia has diversified Vertex's commercial opportunities [8] - The company is also focusing on the pain asset suzetrigine, which is believed to have blockbuster potential, with a rolling new drug application (NDA) submission process underway [10] Group 3: Regulatory Developments - Vertex's NDA for vanza triple therapy for CF has been accepted by the FDA, with a decision expected on January 2, 2025 [11] - The company is also seeking to expand suzetrigine's indications for various neuropathic pain conditions [26] Group 4: Financial Performance and Valuation - Vertex's revenues are expected to be driven by strong sales of Trikafta/Kaftrio, estimated at $2.4 billion for the upcoming quarter [22] - The stock has increased by 21.7% year-to-date, outperforming the industry and the S&P 500 [28] - Vertex currently trades at a premium to the industry, with a price/sales ratio of 12.7 compared to the industry's 2.62 [29] Group 5: Investment Outlook - Vertex's strong CF portfolio and pipeline progress indicate significant growth opportunities [27] - The company is seen as a solid investment based on its financial performance and pipeline developments, with recommendations to retain the stock regardless of the upcoming quarterly results [32]

Core Viewpoint - Vertex Pharmaceuticals is expected to report strong earnings and revenue growth in the upcoming earnings release, indicating a positive outlook for the company [2][3]. Group 1: Recent Performance - Vertex Pharmaceuticals closed at $490.80, reflecting a slight increase of +0.1% from the previous trading day, outperforming the S&P 500's decline of 2.32% [1]. - Over the past month, Vertex shares have gained 3.48%, while the Medical sector and S&P 500 saw gains of 0.32% and 1.79%, respectively [1]. Group 2: Earnings Estimates - The upcoming earnings report on August 1, 2024, is anticipated to show an EPS of $4.11, representing a 5.66% increase year-over-year [2]. - Revenue is expected to reach $2.65 billion, marking a 6.19% rise compared to the same quarter last year [2]. - For the full year, earnings are projected at $17.02 per share and revenue at $10.73 billion, reflecting increases of +11.75% and +8.74% from the previous year [3]. Group 3: Valuation Metrics - Vertex Pharmaceuticals has a Forward P/E ratio of 28.82, which is higher than the industry average of 24.23 [6]. - The company has a PEG ratio of 2.25, closely aligned with the industry average PEG ratio of 2.26 [7]. Group 4: Industry Context - The Medical - Biomedical and Genetics industry, which includes Vertex Pharmaceuticals, holds a Zacks Industry Rank of 85, placing it in the top 34% of over 250 industries [8]. - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]. Group 5: Analyst Estimates - Recent changes in analyst estimates for Vertex Pharmaceuticals suggest a positive business outlook, as these revisions often reflect short-term business dynamics [10].

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this drugmaker have returned +3.5% over the past month versus the Zacks S&P 500 composite's +1.8% change. The Zacks Medical - Biomedical and Genetics industry, to which Vertex belongs, has gained 3.9% over this period. Now the key question is: Where could the stock be headed in the near term? Earni ...

Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 1, 2024. The company is expected to report EPS of $4.14, up 6.43% from the prior-year quarter. Meanwhile, the latest consensus estimate predicts the revenue to be $2.64 billion, indicating a 6.01% increase compared to the same quarter of the previous year. The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), po ...

- Three-year extension of collaboration to use genomics to accelerate drug discovery - - The range of therapeutic areas and genomic data insights will be expanded and the companies will also explore using genomic risk to better define patient subgroups - OXFORD, England, July 16, 2024 /PRNewswire/ -- Genomics plc (Genomics), a healthcare company transforming health through the power of genomics today announced a three-year extension of the company's collaboration with Vertex Pharmaceuticals Incorporated (Ve ...

Vertex Pharmaceuticals (VRTX) closed at $490.85 in the latest trading session, marking a +0.43% move from the prior day. The stock's change was more than the S&P 500's daily gain of 0.28%. Elsewhere, the Dow saw an upswing of 0.53%, while the tech-heavy Nasdaq appreciated by 0.4%. Investors will be eagerly watching for the performance of Vertex Pharmaceuticals in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 1, 2024. The company is predicted to post an EPS o ...

So far this year, the stock has risen 16.5% against the industry's 4.6% decline. The stock has also outperformed the sector as well as the S&P 500. Estimates for Vertex's 2024 earnings have moved up from $16.88 to $17.06 over the past 60 days. New Products on the Way VRTX Stock Valuation Vertex is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress. Consistently rising earnings estimates clearly highlight analysts' optimism about its abilit ...